2Therasse P, Arbuek SG, Eiscilhauer EA, et al. New guide- lines to evaluate the response to treatment in solid tumor [ J ]. J Natl Cancer Inst ,2000 ,92 (3) :205 - 216.
2[2]Thoms J,Lynch M D,Daphne W,et al.Activatiny mutations in the epidermal grouth factor receptor underlying responsiveness of non-small call lung cancer to gefitinib[J].New Eng J Med,2004,350(21):2129-2193.
3[3]Chiu CH,Tsai CM,Chen YM,et al.Gefitinib is active in patients with brain metastases from non-small cell cancer and respon is related to skin toxicity[J].Lung Cancer,2005,47(1):129-138.
4Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib[J]. Lung Cancer, 2004,45(1) : 93- 104.
5Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2) :92-98.
6Massarelli E, Andre F, Liu D D, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-smallcell lung cancer[J]. Lung Cancer, 2003, 39(1):55-61.
7Yarden Y, Sliwkowski M X. Untangling the ErbB signaling network[J]. Nat Rev Mol Cell Biol, 2001,127-137.
8Fukouka M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839 (Iressa) for patiets with advanced nonsmall cell lung cancer (IDEAL 1)(abstract 1188)[J]. Proc Am Soc Clin Oncol, 2002,21 : 298a
9KrisMG, Natale R B, Herbst R S, et al. A phaseⅡ trial of ZD1839 (Iressa) in advanced non-small cell lung cancer(NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2)(abstract 1166)[J]. Proc Am Soc Clin Oncol, 2002,21:292.
10AstraZeneca Oncology. IRESSA survival evaluation in lung cancer (ISEL 709).
